ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.922,11
0,00%
S&P 500
5.948,71
0,53%
US Dollar vs BRL
5,8242
0,15%
Bitcoin
98.791,09
0,28%
Brent Oil
73,30
-0,85%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Xenon Pharmaceuticals Inc (XENE)

  7. Xenon Pharmaceuticals Inc (XENE) Notícias

XENE

Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:XENE
DataHoraFonteTítuloCódigoCompanhia
13/11/202418:01GlobeNewswire Inc.Xenon to Present at Upcoming Investor ConferencesNASDAQ:XENEXenon Pharmaceuticals Inc
12/11/202418:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XENEXenon Pharmaceuticals Inc
12/11/202418:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
12/11/202418:01GlobeNewswire Inc.Xenon Reports Q3 2024 Financial Results and Business UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
05/11/202418:01GlobeNewswire Inc.Xenon to Report Q3 2024 Financial Results on November 12, 2024NASDAQ:XENEXenon Pharmaceuticals Inc
02/10/202417:28GlobeNewswire Inc.Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
09/09/202409:30GlobeNewswire Inc.Xenon Showcases Azetukalner Data at 15th European Epilepsy CongressNASDAQ:XENEXenon Pharmaceuticals Inc
12/08/202409:30GlobeNewswire Inc.Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating OfficerNASDAQ:XENEXenon Pharmaceuticals Inc
09/08/202417:57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:XENEXenon Pharmaceuticals Inc
08/08/202417:01GlobeNewswire Inc.Xenon Reports Q2 2024 Financial Results and Business UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
01/08/202417:01GlobeNewswire Inc.Xenon to Report Q2 2024 Financial Results on August 8, 2024NASDAQ:XENEXenon Pharmaceuticals Inc
12/07/202422:44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
05/06/202418:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
05/06/202417:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XENEXenon Pharmaceuticals Inc
05/06/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
28/05/202409:30GlobeNewswire Inc.Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
09/05/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
08/05/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
07/05/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
02/05/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
16/04/202409:30GlobeNewswire Inc.Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
04/04/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
12/03/202417:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysNASDAQ:XENEXenon Pharmaceuticals Inc
05/03/202418:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
29/02/202418:01GlobeNewswire Inc.Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
22/02/202418:01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
14/02/202411:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XENEXenon Pharmaceuticals Inc
08/01/202410:00GlobeNewswire Inc.Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024NASDAQ:XENEXenon Pharmaceuticals Inc
03/01/202410:30GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
04/12/202318:16GlobeNewswire Inc.Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:XENEXenon Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:XENE

Seu Histórico Recente

TG
CHK
China Resources Beer
TSX
DII.B
Dorel Industries
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados